<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="147972">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01881087</url>
  </required_header>
  <id_info>
    <org_study_id>LevoBupi-003</org_study_id>
    <nct_id>NCT01881087</nct_id>
  </id_info>
  <brief_title>Spinal Anesthesia With Hyperbaric Levobupivacaine 0.75% for Ambulatory Knee Arthroscopy</brief_title>
  <acronym>levobupi</acronym>
  <official_title>Spinal Anesthesia With Hyperbaric Levobupivacaine 0.75% for Ambulatory Knee Arthroscopy: A Double Blind, Randomized Clinical Trial Comparing Three Low Doses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Clinica Valle del Lili</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Clinica Valle del Lili</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate motor block probability throughout time and
      clinical profile when using three different doses of HLBP 0.75% (7.5, 9.37 and 11.25 mg) by
      a unilateral spinal block technique.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous IRB approval and informed consent, 180 ASA I-II adults under ambulatory knee
      arthroscopy will be randomly allocated to receive unilateral spinal anesthesia with 7.5
      (group Levo-7.5, n=59), 9.37(group Levo-9.37, n=61) and 11.25 (group Levo-11.25, n=60) mg of
      HLBP 0.75% using a 27-gauge Whitacre needle at a rate of 0.1 ml/ seg. and lateral decubitus
      position maintained for 5 min after injection.

      An independent observer will evaluate motor (modified Bromage scale) and sensory
      (transcutaneal electrical stimulation at T10, L1, L3, and S1 dermal segments) levels and
      presence of adverse events immediately after return to supine, at the end of surgery and
      each 10 min from admission to PACU until home discharge conditions.

      Trans-cutaneal electrical stimulation (TES) will be made with a PNS (Ministim® model MS- IV,
      Organon, Dublin, Irland) using 50-Hz tetanus stimuli for 5 seg. from 10 to 60 mA 3,4.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Probability of motor block</measure>
    <time_frame>200 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Likelihood Rate of motor block persistence after a dosis of spinal HLBP 0.75%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Failed Spinal Block Rate</measure>
    <time_frame>15 minutes after dose</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Failed Spinal Block Rate for each treatment group</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Disorder of Knee</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Levo-7.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperbaric Levobupivacaine 0.75% Spinal Administration by a Whitacre Needle 27G. Dosage:  7.5 mg. Single Dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levo-9.37</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperbaric Levobupivacaine 0.75% Spinal Administration by a Whitacre Needle 27G. Dosage:  9.37 mg. Single Dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levo-11.25</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hyperbaric Levobupivacaine 0.75% Spinal Administration by a Whitacre Needle 27G. Dosage:  11.25 mg. Single Dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperbaric Levobupivacaine 0.75%</intervention_name>
    <description>Each 4 ml of the administred solution contains:  Chlorhydrate Levogyre Bupivacaine 30 mg, Glucose 290.8 mg and water for injection c.s.</description>
    <arm_group_label>Levo-7.5 mg</arm_group_label>
    <arm_group_label>Levo-9.37</arm_group_label>
    <arm_group_label>Levo-11.25</arm_group_label>
    <other_name>Bupinest 0.75% Pesado</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18-64 y.o. scheduled for knee arthroscopy (therapeutic or diagnostic)

        Exclusion Criteria:

          -  Cardiac or pulmonary disease

          -  Antiplatelet or anticoagulant drugs use during 7 days before surgery

          -  History of coagulative disorders

          -  Bilateral procedures
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fredy J Ariza, MD., MSc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación Valle del Lili</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marisol Badiel, MD., MSc.</last_name>
    <role>Study Chair</role>
    <affiliation>Unidad de Investigaciones Clínicas, Fundación Valle del Lili</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundación Valle del Lili</name>
      <address>
        <city>Cali</city>
        <state>Valle del Cauca</state>
        <zip>76001000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <link>
    <url>http://www.redalyc.org/articulo.oa?id=195119002005</url>
    <description>http://apps.elsevier.es/watermark/ctl_servlet?_f=10&amp;pident_articulo=90150010&amp;pident_usuario=0&amp;pcontactid=&amp;pident_revista=341&amp;ty=7&amp;accion=L&amp;origen=reuma%20&amp;web=http://www.revcolanest.com.co&amp;lan=es&amp;fichero=341v38n04a90150010pdf001.pdf</description>
  </link>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 19, 2013</lastchanged_date>
  <firstreceived_date>June 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinica Valle del Lili</investigator_affiliation>
    <investigator_full_name>Fredy Ariza</investigator_full_name>
    <investigator_title>Anesthesiologist, Epidemiologist</investigator_title>
  </responsible_party>
  <keyword>Knee Arthroscopy</keyword>
  <keyword>Levobupivacaine</keyword>
  <keyword>Spinal Anesthesia</keyword>
  <keyword>Motor Block</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
